154 related articles for article (PubMed ID: 21853049)
1. Treatment of inflammatory bowel disease associated E. coli with ciprofloxacin and E. coli Nissle in the streptomycin-treated mouse intestine.
Petersen AM; Schjørring S; Gerstrøm SC; Krogfelt KA
PLoS One; 2011; 6(8):e22823. PubMed ID: 21853049
[TBL] [Abstract][Full Text] [Related]
2. Precolonized human commensal Escherichia coli strains serve as a barrier to E. coli O157:H7 growth in the streptomycin-treated mouse intestine.
Leatham MP; Banerjee S; Autieri SM; Mercado-Lubo R; Conway T; Cohen PS
Infect Immun; 2009 Jul; 77(7):2876-86. PubMed ID: 19364832
[TBL] [Abstract][Full Text] [Related]
3. Escherichia coli EDL933 requires gluconeogenic nutrients to successfully colonize the intestines of streptomycin-treated mice precolonized with E. coli Nissle 1917.
Schinner SA; Mokszycki ME; Adediran J; Leatham-Jensen M; Conway T; Cohen PS
Infect Immun; 2015 May; 83(5):1983-91. PubMed ID: 25733524
[TBL] [Abstract][Full Text] [Related]
4. Nutritional basis for colonization resistance by human commensal Escherichia coli strains HS and Nissle 1917 against E. coli O157:H7 in the mouse intestine.
Maltby R; Leatham-Jensen MP; Gibson T; Cohen PS; Conway T
PLoS One; 2013; 8(1):e53957. PubMed ID: 23349773
[TBL] [Abstract][Full Text] [Related]
5. Ciprofloxacin and probiotic Escherichia coli Nissle add-on treatment in active ulcerative colitis: a double-blind randomized placebo controlled clinical trial.
Petersen AM; Mirsepasi H; Halkjær SI; Mortensen EM; Nordgaard-Lassen I; Krogfelt KA
J Crohns Colitis; 2014 Nov; 8(11):1498-505. PubMed ID: 24972748
[TBL] [Abstract][Full Text] [Related]
6. Intestinal colonization with phylogenetic group B2 Escherichia coli related to inflammatory bowel disease: a systematic review and meta-analysis.
Petersen AM; Halkjær SI; Gluud LL
Scand J Gastroenterol; 2015; 50(10):1199-207. PubMed ID: 25910859
[TBL] [Abstract][Full Text] [Related]
7. An Escherichia coli Nissle 1917 missense mutant colonizes the streptomycin-treated mouse intestine better than the wild type but is not a better probiotic.
Adediran J; Leatham-Jensen MP; Mokszycki ME; Frimodt-Møller J; Krogfelt KA; Kazmierczak K; Kenney LJ; Conway T; Cohen PS
Infect Immun; 2014 Feb; 82(2):670-82. PubMed ID: 24478082
[TBL] [Abstract][Full Text] [Related]
8. A Simple
Mokszycki ME; Leatham-Jensen M; Steffensen JL; Zhang Y; Krogfelt KA; Caldwell ME; Conway T; Cohen PS
Appl Environ Microbiol; 2018 Dec; 84(24):. PubMed ID: 30291119
[TBL] [Abstract][Full Text] [Related]
9. Escherichia coli Nissle 1917 ghosts alleviate inflammatory bowel disease in zebrafish.
Chen H; Lei P; Ji H; Ma J; Fang Y; Yu H; Du J; Qu L; Yang Q; Luo L; Zhang K; Wu W; Jin L; Sun D
Life Sci; 2023 Sep; 329():121956. PubMed ID: 37473802
[TBL] [Abstract][Full Text] [Related]
10. L-fucose stimulates utilization of D-ribose by Escherichia coli MG1655 DeltafucAO and E. coli Nissle 1917 DeltafucAO mutants in the mouse intestine and in M9 minimal medium.
Autieri SM; Lins JJ; Leatham MP; Laux DC; Conway T; Cohen PS
Infect Immun; 2007 Nov; 75(11):5465-75. PubMed ID: 17709419
[TBL] [Abstract][Full Text] [Related]
11. Reduced microbial diversity and high numbers of one single Escherichia coli strain in the intestine of colitic mice.
Wohlgemuth S; Haller D; Blaut M; Loh G
Environ Microbiol; 2009 Jun; 11(6):1562-71. PubMed ID: 19245530
[TBL] [Abstract][Full Text] [Related]
12. Bacteroides vulgatus protects against Escherichia coli-induced colitis in gnotobiotic interleukin-2-deficient mice.
Waidmann M; Bechtold O; Frick JS; Lehr HA; Schubert S; Dobrindt U; Loeffler J; Bohn E; Autenrieth IB
Gastroenterology; 2003 Jul; 125(1):162-77. PubMed ID: 12851881
[TBL] [Abstract][Full Text] [Related]
13. Neither motility nor chemotaxis plays a role in the ability of Escherichia coli F-18 to colonize the streptomycin-treated mouse large intestine.
McCormick BA; Laux DC; Cohen PS
Infect Immun; 1990 Sep; 58(9):2957-61. PubMed ID: 2201640
[TBL] [Abstract][Full Text] [Related]
14. Clinical use of E. coli Nissle 1917 in inflammatory bowel disease.
Schultz M
Inflamm Bowel Dis; 2008 Jul; 14(7):1012-8. PubMed ID: 18240278
[TBL] [Abstract][Full Text] [Related]
15. Escherichia coli B2 strains prevalent in inflammatory bowel disease patients have distinct metabolic capabilities that enable colonization of intestinal mucosa.
Fang X; Monk JM; Mih N; Du B; Sastry AV; Kavvas E; Seif Y; Smarr L; Palsson BO
BMC Syst Biol; 2018 Jun; 12(1):66. PubMed ID: 29890970
[TBL] [Abstract][Full Text] [Related]
16. Chemostat modeling of Escherichia coli persistence in conventionalized mono-associated and streptomycin-treated mice.
Rang C; Midtvedt T; Molin S; Chao L
Can J Microbiol; 2001 Jan; 47(1):86-90. PubMed ID: 15049455
[TBL] [Abstract][Full Text] [Related]
17. 5-Aminosalicylic acid downregulates the growth and virulence of Escherichia coli associated with IBD and colorectal cancer, and upregulates host anti-inflammatory activity.
Zhang S; Fu J; Dogan B; Scherl EJ; Simpson KW
J Antibiot (Tokyo); 2018 Nov; 71(11):950-961. PubMed ID: 30050110
[TBL] [Abstract][Full Text] [Related]
18. Effect of antibiotic, probiotic, and human rotavirus infection on colonisation dynamics of defined commensal microbiota in a gnotobiotic pig model.
Huang HC; Vlasova AN; Kumar A; Kandasamy S; Fischer DD; Deblais L; Paim FC; Langel SN; Alhamo MA; Rauf A; Shao L; Saif LJ; Rajashekara G
Benef Microbes; 2018 Jan; 9(1):71-86. PubMed ID: 29022385
[TBL] [Abstract][Full Text] [Related]
19. Relative colonizing abilities of human fecal and K 12 strains of Escherichia coli in the large intestines of streptomycin-treated mice.
Myhal ML; Laux DC; Cohen PS
Eur J Clin Microbiol; 1982 Jun; 1(3):186-92. PubMed ID: 6756909
[TBL] [Abstract][Full Text] [Related]
20. The ability of rifampin-resistant Escherichia coli to colonize the mouse intestine is enhanced by the presence of a plasmid-encoded aerobactin-iron(III) uptake system.
Stojiljković I; Cobeljić M; Trgovcević Z; Salaj-Smic E
FEMS Microbiol Lett; 1991 Dec; 69(1):89-93. PubMed ID: 1783288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
